The potential economic value of a Trypanosoma cruzi (chagas disease) vaccine in Latin America

PLoS Neglected Tropical Diseases

Volumn 4, Issue 12, 2010, Pages 1-8

  Lee, Bruce Y ^a,b   Bacon, Kristina M ^a,b   Connor, Diana L ^a,b   Willig, Alyssa M ^a,b   Bailey, Rachel R ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRYPANOSOMA CRUZI VACCINE; PROTOZOAL VACCINE;

ARTICLE; CHAGAS DISEASE; COMPUTER MODEL; COMPUTER SIMULATION; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISABILITY ADJUSTED LIFE YEAR; DRUG COST; DRUG EFFICACY; INFECTION RISK; QUALITY OF LIFE; SOUTH AND CENTRAL AMERICA; ADOLESCENT; ADULT; AGED; CHILD; ECONOMICS; FEMALE; HUMAN; IMMUNOLOGY; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; STATISTICAL MODEL; TRYPANOSOMA CRUZI;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHAGAS DISEASE; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LATIN AMERICA; MIDDLE AGED; MODELS, STATISTICAL; PROTOZOAN VACCINES; TRYPANOSOMA CRUZI; YOUNG ADULT;

EID: 78650707764     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000916     Document Type: Article

References (28)

1. Sosa-Estani S, Viotti R, Segura EL (2009) Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz 104 Suppl 1: 167-180.
2. Cubillos-Garzon LA, Casas JP, Morillo CA, Bautista LE (2004) Congestive heart failure in Latin America: the next epidemic. Am Heart J 147: 412-417.
3. Marin Neto JA, Simoes MV, Sarabanda AV (1999) Chagas' heart disease. Arq Bras Cardiol 72: 247-280.
4. Wanderley DM, Correa FM (1995) Epidemiology of Chagas' heart disease. Sao Paulo Med J 113: 742-749.
5. Rassi A, Jr., Rassi A, Marin-Neto JA (2010) Chagas disease. Lancet 375: 1388-1402.
6. Wilson LS, Strosberg AM, Barrio K (2005) Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models. Am J Trop Med Hyg 73: 901-910.
7. Urbina JA (2009) New advances in the management of a long-neglected disease. Clin Infect Dis 49: 1685-1687.
8. Coura JR (2007) Chagas disease: what is known and what is needed-a background article. Mem Inst Oswaldo Cruz 102 Suppl 1: 113-122.
9. Cancado JR (2002) Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44: 29-37.
10. Guhl F, Vallejo GA (1999) Interruption of Chagas disease transmission in the Andean countries: Colombia. Mem Inst Oswaldo Cruz 94 Suppl 1: 413-415.
11. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE (2007) The challenges of Chagas Diseasegrim outlook or glimmer of hope. PLoS Med 4: e332.
12. Dumonteil E (2007) DNA Vaccines against Protozoan Parasites: Advances and Challenges. J Biomed Biotechnol 2007: 90520.
13. Giddings OK, Eickhoff CS, Sullivan NL, Hoft DF (2010) Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges. Infect Immun 78: 1333-1338.
14. Lee BY, Burke DS (2010) Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 28: 2806-2809.
15. Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC (2007) Clinical aspects of the Chagas' heart disease. Int J Cardiol 115: 279-283.
16. Castillo-Riquelme M, Guhl F, Turriago B, Pinto N, Rosas F, et al. (2008) The costs of preventing and treating chagas disease in Colombia. PLoS Negl Trop Dis 2: e336.
17. Hidron AI, Gilman RH, Justiniano J, Blackstock AJ, Lafuente C, et al. (2010) Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis 4: e688.
18. International Monetary Fund (2010) World Economic and Financial Surveys World Economic Outlook Database.
19. United Nations Childrens Fund (UNICEF) (2008) UNICEF - Colombia - Statistics.
20. Goldman N, Heuveline P (2000) Health-seeking behaviour for child illness in Guatemala. Trop Med Int Health 5: 145-155.
21. World Health Organization: Global Health Observatory (2008) Colombia.
22. World Health Organization (2004) Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. Geneva.
23. Wolfson L, Gasse F, Lee-Martin SP, Lydon P, Magan A, et al. (2008) Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bulletin of the World Health Organization 86: 27-39.
24. Basombrio MA, Schofield CJ, Rojas CL, del Rey EC (1998) A cost-benefit analysis of Chagas disease control in north-western Argentina. Trans R Soc Trop Med Hyg 92: 137-143.
25. Mendez GF, Cowie MR (2001) The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol 80: 213-219.
26. Coura JR (2009) Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem Inst Oswaldo Cruz 104: 549-554.
27. Murray C, Lopez AD (1996) Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for Over 200 Conditions (The Global Burden of Disease and Injury). CambridgeMass: Harvard School of Public Health on behalf of the World Health Organization and the World Bank: Distributed by Harvard University Press.
28. Yun O, Lima MA, Ellman T, Chambi W, Castillo S, et al. (2009) Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis 3: e488.